国: アメリカ合衆国
言語: 英語
ソース: NLM (National Library of Medicine)
norgestimate (UNII: C291HFX4DY) (norgestimate - UNII:C291HFX4DY), ethinyl estradiol (UNII: 423D2T571U) (ethinyl estradiol - UNII:423D2T571U)
Janssen Pharmaceuticals, Inc.
norgestimate
norgestimate 0.18 mg
PRESCRIPTION DRUG
ORTHO TRI-CYCLEN Lo Tablets are indicated for use by females of reproductive potential to prevent pregnancy [see Clinical Studies (14)] . Do not prescribe ORTHO TRI-CYCLEN Lo to women who are known to have the following conditions: - A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1)] Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)] Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)] Have cerebrovascular disease [see Warnings and Precautions (5.1)] Have coronary artery disease [see Warnings and Precautions (5.1)] Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)] Have uncontrolled hypertension [see Warnings and Precautions (5.4)] Have
ORTHO TRI-CYCLEN Lo Tablets are available in a single pouch containing a VERIDATE blister card (refill) of 28 tablets: NDC 50458-251-28. ORTHO TRI-CYCLEN Lo Tablets are packaged in a carton containing 6 pouches and 6 unfilled VERIDATE Tablet Dispensers: NDC 50458-251-06 Each blister card (28 tablets) contains in the following order: ORTHO TRI-CYCLEN Lo Tablets are also available for clinic usage in a VERIDATE Tablet Dispenser (unfilled) and VERIDATE refills: NDC 50458-251-20 and NDC 50458-251-12 ORTHO TRI-CYCLEN Lo Tablets are available in a DIALPAK Tablet Dispenser (unfilled) and DIALPAK refills: NDC 50458-251-00 and NDC 50458-251-15
New Drug Application
ORTHO TRI CYCLEN LO- NORGESTIMATE AND ETHINYL ESTRADIOL JANSSEN PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ORTHO TRI-CYCLEN LO SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ORTHO TRI-CYCLEN LO. ORTHO TRI-CYCLEN LO (NORGESTIMATE/ETHINYL ESTRADIOL) TABLETS FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ ORTHO TRI-CYCLEN LO IS CONTRAINDICATED IN WOMEN OVER 35 YEARS OLD WHO SMOKE. (4) CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVES (COC) USE. (4) RECENT MAJOR CHANGES Contraindications (4) 08/2017 Warnings and Precautions (5.3) 08/2017 INDICATIONS AND USAGE ORTHO TRI-CYCLEN Lo is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. (1.1) DOSAGE AND ADMINISTRATION Take one tablet daily by mouth at the same time every day. (2.2) Take tablets in the order directed on the blister pack. (2.2) Do not skip or delay tablet intake. (2.2) DOSAGE FORMS AND STRENGTHS ORTHO TRI-CYCLEN Lo consists of 28 round, biconvex, coated tablets in the following order (3): 7 white tablets each containing 0.180 mg norgestimate and 0.025 mg ethinyl estradiol 7 light blue tablets each containing 0.215 mg norgestimate and 0.025 mg ethinyl estradiol 7 dark blue tablets each containing 0.250 mg norgestimate and 0.025 mg ethinyl estradiol 7 dark green tablets (inert) CONTRAINDICATIONS A high risk of arterial or venous thrombotic diseases (4) Liver tumors or liver disease (4) Undiagnosed abnormal uterine bleeding (4) Pregnancy (4) Breast cancer or other estrogen- or progestin-sensitive cancer (4) Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir (4) WARNINGS AND PRECAUTIONS Thromboembolic Disorders and Other Vascular Problems: Stop ORTHO TRI-CYCLEN Lo if a thrombotic event o 完全なドキュメントを読む